Clinical trial of vaginal ring for HIV prevention begins in Africa
Researchers are set to conduct clinical trials in Africa to test the effectiveness of a vaginal ring coated with an anti-AIDS drug that could protect women from HIV infection.
Written By Miscellaneous|Last Updated: Jul 25, 2012, 10:10 AM IST|Source: Exclusive
Zeenews Bureau
New Delhi: Researchers are set to conduct clinical trials in Africa to test the effectiveness of a vaginal ring that could protect women from HIV infection.
Giving women tools to protect themselves when their partners won`t use a condom is crucial for battling the epidemic. Women already make up half of the 34.2 million people worldwide living with HIV, even more 60 per cent in hard-hit Africa.
But developing these so-called microbicides has proved a hurdle. Previous research found an anti-AIDS vaginal gel offered partial protection but women may have a hard time using it every time they have sex. The vaginal ring, in contrast, would have to inserted just once a month for ongoing protection prompting hope that it will prove more effective.
The work marks an attempt at "the next generation of women-focused prevention tools," Dr Carl Dieffenbach of the US National Institutes of Health said today in announcing the new research at the International AIDS Conference.
"We need options that fit readily into women`s lives," added Dr Sharon Hillier of the University of Pittsburgh and the Microbide Trials Network, which is conducting the new NIH-funded study.
Developed by the nonprofit International Partnership for Microbicides, the silicone ring contains an anti-AIDS drug named dapivirine, which slowly oozes out into the surrounding vaginal tissue. Unlike vaginal rings sold today in the US, the experimental ring does not contain birth control for now, the focus only is on HIV prevention.
Early-stage studies suggested the ring could work, and women said they liked using it better than a gel, said Dr Saidi Kapiga of the London School of Hygiene and Tropical Medicine.
Now come the large studies needed to prove it.
The NIH-funded study, named ASPIRE, will enroll nearly 3,500 women in Malawi, South Africa, Uganda, Zambia and Zimbabwe. They will receive either a dapivirine-containing vaginal ring or an identical-looking drug-free ring, to be inserted once a month for a year.
The goal is to see if using the ring lowers women`s risk of HIV infection by at least 60 per cent.
The first women in Uganda were enrolled today, Hillier said.
A smaller ring study of 1,650 women got under way last month in South Africa and aims to enroll in Rwanda and Malawi, too.
Vaginal-based protection should cause fewer side effects than pills, and early-stage studies of the ring found no problems, said International Partnership for Microbicides chief executive Zeda Rosenberg. Also, animal studies show no sign that the ring would harm a fetus if a woman became pregnant while using it, she added.
(With Agency inputs)
By clicking “Accept All Cookies”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts.
Cookies Setting
By clicking “Accept All Cookies”, you agree to the storing of cookies on your device and the processing of information obtained via those cookies (including about your preferences, device and online activity) by us and our commercial partners to enhance site navigation, personalise ads, analyze site usage, and assist in our marketing efforts. More information can be found in our Cookies and Privacy Policy. You can amend your cookie settings to reject non-essential cookies by clicking Cookie Settings below.
Manage Consent Preferences
Strictly Necessary Cookies
These cookies are necessary for the website to function and cannot be switched off in our systems. They are usually only set in response to actions made by you which amount to a request for services, such as setting your privacy preferences, logging in or filling in forms. You can set your browser to block or alert you about these cookies, but some parts of the site will not then work or you may not be able to login.
Functional Cookies
These cookies enable the website to provide enhanced functionality and personalisation. They may be set by us or by third party providers whose services we have added to our pages. If you do not allow these cookies then some or all of these services may not function properly.
Targeting Cookies
These cookies may be set through our site by our advertising partners. They may be used by those companies to build a profile of your interests and show you relevant adverts on other sites. They are also used to limit the number of times you see an advert as well as help measure the effectiveness of an advertising campaign. They do not store directly personal information, but are based on uniquely identifying your browser and internet device. If you do not allow these cookies, you will experience less targeted advertising.
Performance Cookies
These cookies allow us to count visits and traffic sources so we can measure and improve the performance of our site. They help us to know which pages are the most and least popular and see how visitors move around the site. All information these cookies collect is aggregated and therefore anonymous. If you do not allow these cookies we may not know when you have visited our site, and may not be able to monitor its performance.